Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
ECOR 
Electrocore LLC (ECOR)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/27/2025: ECOR (3-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Number of Analysts
5 Analysts rated it
These Stocks/ETFs, based on Upturn Advisory, have historically outperformed the market, making them a top-tier choice for investors.
Year Target Price $20.88
Year Target Price $20.88
| 3 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Under performing |
| 0 | Sell |
Analysis of Past Performance
Type Stock | Historic Profit 89.68% | Avg. Invested days 33 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  4.0 |
| Profits based on simulation | Last Close 06/27/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 40.44M USD | Price to earnings Ratio - | 1Y Target Price 20.88 |
Price to earnings Ratio - | 1Y Target Price 20.88 | ||
Volume (30-day avg) - | Beta 0.8 | 52 Weeks Range 4.46 - 19.49 | Updated Date 06/29/2025 |
52 Weeks Range 4.46 - 19.49 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.53 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -46.24% | Operating Margin (TTM) -56.88% |
Management Effectiveness
Return on Assets (TTM) -50.68% | Return on Equity (TTM) -276.15% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 36681852 | Price to Sales(TTM) 1.53 |
Enterprise Value 36681852 | Price to Sales(TTM) 1.53 | ||
Enterprise Value to Revenue 1.39 | Enterprise Value to EBITDA 0.16 | Shares Outstanding 7420620 | Shares Floating 5517155 |
Shares Outstanding 7420620 | Shares Floating 5517155 | ||
Percent Insiders 29.79 | Percent Institutions 18.52 |
Analyst Ratings
Rating 4.6 | Target Price 20.88 | Buy 2 | Strong Buy 3 |
Buy 2 | Strong Buy 3 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Electrocore LLC
Company Overview
History and Background
Electrocore LLC is a commercial-stage bioelectronic medicine company focused on developing non-invasive vagus nerve stimulation (nVNS) therapies. Founded in 2005, the company has developed and commercialized gammaCore, a handheld device used to treat conditions like migraine and cluster headache.
Core Business Areas
- Neuromodulation Therapy: Electrocore focuses on neuromodulation therapies, specifically non-invasive vagus nerve stimulation (nVNS), to treat various medical conditions.
- Medical Device Development and Commercialization: Electrocore develops, manufactures, and commercializes medical devices based on its nVNS technology.
Leadership and Structure
Electrocore's leadership team includes key executives in areas such as research, development, commercial operations, and finance. The organizational structure is focused on innovation and commercialization of its nVNS technology.
Top Products and Market Share
Key Offerings
- gammaCore Sapphire nVNS: A handheld, non-invasive vagus nerve stimulator approved for the acute treatment of migraine and cluster headache. Market share data is not publicly available, but it competes with traditional pharmaceuticals and other neuromodulation devices. Competitors include Cefaly (STIMwave) and pharmaceutical companies like AbbVie (AGN) (Ubrelvy, Qulipta).
Market Dynamics
Industry Overview
The neuromodulation market is growing, driven by increasing demand for non-pharmacological treatments for neurological and psychiatric disorders. Advancements in technology and a growing awareness of the potential benefits of neuromodulation are fueling this growth.
Positioning
Electrocore is a key player in the non-invasive neuromodulation market with its gammaCore device. Their competitive advantage lies in its FDA-cleared device for acute headache treatment and its non-pharmacological approach.
Total Addressable Market (TAM)
The global neuromodulation market is expected to reach billions of dollars. Electrocore is positioned to capture a portion of this TAM with its focused approach on headache and migraine treatment.
Upturn SWOT Analysis
Strengths
- FDA-cleared device for migraine and cluster headache
- Non-invasive treatment option
- Proprietary nVNS technology
- Experienced leadership team
Weaknesses
- Limited product portfolio
- Reliance on gammaCore sales
- Need for strong marketing and sales efforts
- Reimbursement challenges with insurance providers
Opportunities
- Expansion into new therapeutic areas (e.g., PTSD, epilepsy)
- Partnerships with pharmaceutical companies
- Geographic expansion into new markets
- Development of next-generation nVNS devices
Threats
- Competition from established pharmaceutical companies
- Evolving regulatory landscape
- Technological advancements in competing neuromodulation devices
- Potential for generic versions of gammaCore
Competitors and Market Share
Key Competitors
- STIMwave (Privately held, Cefaly device)
- AbbVie (ABBV)
- Amgen (AMGN)
Competitive Landscape
Electrocore faces competition from pharmaceutical companies offering migraine medications and other neuromodulation device manufacturers. Electrocore's advantage lies in its non-invasive approach, but it faces challenges in reimbursement and market adoption.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is dependent on gammaCore adoption and market penetration.
Future Projections: Future growth is dependent on expansion into new indications, partnerships, and reimbursement success.
Recent Initiatives: Recent initiatives include pursuing new clinical trials for other indications and expanding market access.
Summary
Electrocore LLC is a niche player in the neuromodulation market with a focus on non-invasive vagus nerve stimulation for headache treatment. The company's key strength is its FDA-cleared gammaCore device. Challenges include limited product portfolio, reimbursement hurdles, and competition from established pharmaceutical companies. Future growth hinges on expanding into new indications and securing favorable reimbursement policies.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Electrocore LLC Website
- Industry Reports
- Analyst Reports
Disclaimers:
The information provided is for informational purposes only and does not constitute financial advice. Market share data is based on estimates and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Electrocore LLC
Exchange NASDAQ | Headquaters Rockaway, NJ, United States | ||
IPO Launch date 2018-06-22 | CEO & Director Mr. Daniel S. Goldberger | ||
Sector Healthcare | Industry Medical Devices | Full time employees 73 | Website https://www.electrocore.com |
Full time employees 73 | Website https://www.electrocore.com | ||
electroCore, Inc., a bioelectronic medicine and general wellness company, provides non-invasive vagus nerve stimulation ("nVNS") technology platform in the United States, the United Kingdom, and internationally. The company develops gammaCore, a prescription only handheld device intended for regular or intermittent use for the acute treatment of pain associated with migraine and episodic cluster headache, as well as for the treatment of hemicrania continua and paroxysmal hemicrania. It also develops Truvaga 350, a personal use consumer electronics general wellness product and Truvaga Plus, an, app-enabled general wellness product. It also offers non-invasive bioelectronic therapies for the treatment of chronic pain and wellness conditions. In addition, the company offers TAC-STIM for human performance and gammaCore Sapphire, a portable, reusable, rechargeable, and reloadable prescription medical device for various primary headache conditions. electroCore, Inc. was incorporated in 2005 and is headquartered in Rockaway, New Jersey.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.